Indivior Pharmaceuticals Inc (INDV) は上場企業です ヘルスケア セクターの Drug Manufacturers - Specialty & Generic 業界で事業展開. 本社所在地は North Chesterfield, VA, アメリカ. 現CEOは Joseph J. Ciaffoni.
INDV を有する IPO日 2014-12-29, 1,030 名の正社員, に上場 NASDAQ Global Select, 時価総額 $4.06B.
Indivior PLC is a specialty pharmaceutical company focused on developing and commercializing prescription medications for substance use disorders, serious mental illnesses, and opioid overdose. The company's marketed portfolio includes SUBLOCADE and SUBUTEX PRO, buprenorphine extended-release monthly injections; SUBOXONE sublingual films and tablets; SUBUTEX sublingual tablets; OPVEE nasal spray for opioid overdose reversal; and PERSERIS for schizophrenia treatment. Indivior maintains a robust pipeline with multiple clinical and preclinical programs, including INDV-2000 for opioid use disorder, INDV-1000 for alcohol use disorder, and several collaborative development programs addressing opioid, cannabis, and other substance use disorders. Headquartered in North Chesterfield, Virginia, the company operates across the United States, United Kingdom, and international markets.
